Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 118.00 | |
5 mg | In stock | $ 287.00 | |
10 mg | In stock | $ 457.00 | |
25 mg | In stock | $ 753.00 | |
50 mg | In stock | $ 1,060.00 | |
100 mg | In stock | $ 1,430.00 |
Description | MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM). |
Targets&IC50 | MYC:3.2 μM(Kd) |
In vitro | MYCi361 is a small-molecule MYC inhibitors that inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC50 values[1]. |
In vivo | MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. |
Animal Research | FVB or NSG male mice of 6-8 weeks of age and 25 g bearing established MycCaP tumors.MYCi361 treatment i.p. initially at 50 mg/kg twice daily for 2 days, then 70 mg/kg/day for 9 days |
Synonyms | NUCC-0196361 |
Molecular Weight | 594.86 |
Formula | C26H16ClF9N2O2 |
CAS No. | 2289690-31-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (168.1 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MYCi361 2289690-31-7 Cell Cycle/Checkpoint c-Myc MYCi 361 NUCC0196361 NUCC 0196361 MYCi-361 NUCC-0196361 inhibit Inhibitor Myc inhibitor